Laurie Toich, Assistant Editor

A malaria protein combined with an anti-cancer drug shows promise against chemotherapy-resistant bladder cancer.

Combination treatment shows promise fighting bladder cancer.

Top news of the day from across the healthcare landscape.

The Kisqali Femara Co-Pack is the only approved combination pack that includes 2 prescription drugs used to treat breast cancer.

Patients with HIV on ART may have high viral levels, immune activation, and inflammation.

Steroids discovered in dietary supplements distributed from 2015 to 2017.

Top news of the day from across the healthcare landscape.

Manufacturers and payers face regulatory and operational barriers for value-based contracts.

World Health Organization reports lack of uptake of hepatitis treatments.

Eating animal protein may increase the risk of non-alcoholic fatty liver disease development.

Many patients have low adherence to statins more than 2 years after a heart attack.

FDA authorizes an omalizumab (Xolair) biosimilar to commence clinical trials.

GBR 310 is a recombinant DNA-derived monoclonal antibody for the treatment of allergic asthma and chronic idiopathic urticaria.

Prescriptions increased 19% after only 1.5 years of Medicaid expansion.

Ledipasvir/sofosbuvir combination resulted in beneficial viral response in pediatric patients.

Tighter regulations surrounding opioids have presented a challenge to physicians treating chronic pain.

Liquid cannabidiol reduced seizures up to 50% in some patients with Lennox-Gastaut syndrome.

New analyses show the benefits of early treatment with Tefidera (dimethyl fumarate) and Tysabri (natalizumab).

Interleukin cytokine involved with inflammatory bowel disease pathology.

Plant protein may decrease the risk of type 2 diabetes.

Pitavastatin reduced LDL cholesterol with little impact on HIV-1 RNA and CD4 cell counts.

Pitavastatin lowered LDL cholesterol levels in patients with HIV and dyslipidemia.

Study shows the importance of evaluating a drug’s ability to address and reduce MS relapses, lesions, disability progression

Fingolimod (Gilenya) reduced disease progression in patients with relapsing-remitting multiple sclerosis.

Cerliponase alfa (Brineura) is the first treatment approved to treat a form of Batten disease.

Methotrexate oral solution (Xatmep) indicated to treat pediatric patients.

A patient discusses the struggle of receiving treatment for triple negative breast cancer in a rural community.

Cerliponase alfa (Brineura) is the first treatment approved to treat a form of Batten disease.

Anthem searching for new pharmacy benefit manager to take over for Express Scripts in 2020.

US Preventive Services Task Force and American College of Cardiology/American Heart Association change statin eligibility.